{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T13:41:57Z","timestamp":1776606117316,"version":"3.51.2"},"reference-count":0,"publisher":"International Union Against Tuberculosis and Lung Disease","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["int j tuberc lung dis"],"published-print":{"date-parts":[[2017,12,1]]},"abstract":"<jats:p>SETTING: To compare renal insufficiency among multidrug-resistant tuberculosis (MDR-TB) patients treated with kanamycin (KM) based regimens and those treated concomitantly with tenofovir disoproxil fumarate (TDF) or other antiretroviral therapy (ART) regimens in Namibia.DESIGN:\n Retrospective review of the treatment records and laboratory tests of patients initiated on MDR-TB treatment (January\u2013December 2014). The glomerular filtration rates (eGFR) estimated pre- and post-treatment were compared using the analysis of variance test. Renal insufficiency was defined\n as an eGFR of &lt;60 ml\/min\/1.73 m<jats:sup>2<\/jats:sup>. Use of KM or TDF and association with renal insufficiency was assessed using Kaplan-Meier plots and Cox proportional hazards analysis.RESULTS: The baseline mean eGFR for the three groups was similar (<jats:italic>P<\/jats:italic> = 0.24): 139.3 \u00b1 25.6\n ml\/min for the KM group (<jats:italic>n<\/jats:italic> = 68), 131.1 \u00b1 25.7 ml\/min for the KM+TDF group (<jats:italic>n<\/jats:italic> = 44) and 134.2\u00b134.4 ml\/min for the KM+Other group (<jats:italic>n<\/jats:italic> = 23). After 8 months, the values had declined significantly to respectively 104.8 \u00b1 37.5 ml\/min (<jats:italic>P<\/jats:italic> &lt; 0.001),\n 101.5 \u00b1 38.3 ml\/min (<jats:italic>P<\/jats:italic> &lt; 0.001) and 111.5 \u00b1 41.7 ml\/min (<jats:italic>P<\/jats:italic> = 0.01). Co-treatment with KM+ART was associated with an increased risk of renal insufficiency (hazard ratio [HR] 1.8, 95%CI 0.7\u20134.1, <jats:italic>P<\/jats:italic> = 0.20 for KM+TDF, and HR 3.5, 95%CI 1.4\u20138.2,\n <jats:italic>P<\/jats:italic> = 0.005 for KM+Other ART).CONCLUSION: Renal function declined at a similar rate in MDR-TB patients treated with KM-based regimens compared with patients treated concomitantly with TDF-based or other ART. The risk of renal insufficiency was greater for patients on ART.<\/jats:p>","DOI":"10.5588\/ijtld.16.0953","type":"journal-article","created":{"date-parts":[[2018,1,3]],"date-time":"2018-01-03T12:38:29Z","timestamp":1514983109000},"page":"1245-1250","source":"Crossref","is-referenced-by-count":5,"title":["Renal function of MDR-TB patients treated with kanamycin regimens or concomitantly with antiretroviral agents"],"prefix":"10.5588","volume":"21","author":[{"given":"E. L.","family":"Sagwa","sequence":"first","affiliation":[{"name":"Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Ruswa","sequence":"additional","affiliation":[{"name":"National Tuberculosis and Leprosy Program, Ministry of Health and Social Services, Windhoek, Namibia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Mavhunga","sequence":"additional","affiliation":[{"name":"National Tuberculosis and Leprosy Program, Ministry of Health and Social Services, Windhoek, Namibia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Rennie","sequence":"additional","affiliation":[{"name":"University of Namibia School of Pharmacy, Windhoek, Namibia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Mengistu","sequence":"additional","affiliation":[{"name":"Operations Research and Program Monitoring, Directorate of Special Programmes, Ministry of Health and Social Services, Windhoek, Namibia; National HIV and STI Control Programme, Ministry of Health and Social Services, Windhoek, Namibia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. T.","family":"Mekonen","sequence":"additional","affiliation":[{"name":"National HIV and STI Control Programme, Ministry of Health and Social Services, Windhoek, Namibia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. G. M.","family":"Leufkens","sequence":"additional","affiliation":[{"name":"Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands; Medicines Evaluation Board, Utrecht, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. K.","family":"Mantel-Teeuwisse","sequence":"additional","affiliation":[{"name":"Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3554","container-title":["The International Journal of Tuberculosis and Lung Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/iuatld\/ijtld\/2017\/00000021\/00000012\/art00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,23]],"date-time":"2020-01-23T04:53:49Z","timestamp":1579755229000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.5588\/ijtld.16.0953"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,1]]},"references-count":0,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12,1]]}},"alternative-id":["1027-3719(20171201)21:12L.1245;1-"],"URL":"https:\/\/doi.org\/10.5588\/ijtld.16.0953","relation":{},"ISSN":["1027-3719"],"issn-type":[{"value":"1027-3719","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12,1]]}}}